Therapeutic Solutions International CEO
Issues Shareholder Letter
OCEANSIDE, CA --
December 31, 2018 --
InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) addresses
shareholders in letter form.
We have had a
whirlwind of a year in discovery and amazement at TSOI and we are
optimistic for the coming year. I thought I would
address just some of the major accomplishments this year
brought.
In May of this year,
President Donald J. Trump signed into law the "Right
To
Try" Act
and TSOI responded by announcing we would move to offer our
immunotherapy platform "StemVacs". We were
also
honored
to appoint Dr. James Veltmeyer as Chief Medical Officer to head up
all of our RTT programs.
During
the
spring and summer,
we
conducted two small studies of NanoStilbene, our nanoparticle
pterostilbene product. One was a pharmacokinetic study comparing
NanoStilbene (a liquid form) with traditional powder form
pterostilbene. We took two groups of healthy volunteers and gave
one group 300 milligrams (mg) in capsule form and the other group
10 milliliters of NanoStilbene which also
contains
300mg of nanoparticle pterostilbene and studied their blood across
time. We were pleased
to see
that compared to powder, NanoStilbene at peak blood concentration
was 55% greater than the powder form at its peak, and even more
pleased at the half-life being double of powder.
In a second clinical
study of NanoStilbene
in
advanced cancer patients, we sought to
determine whether administration of our
nanoparticle
formulation of pterostilbene may reverse cancer associated
suppression of NK cell (natural killer cell)
activity. We concluded that
study mid-summer using the same dose as was used
pharmacokinetically and we are currently preparing to submit our
manuscript for publication in a medical journal validating
NanoStilbene as an adjuvant to chemo and immunotherapy.
We also
filed 3
additional provisional patent applications on the use of
pterostilbene during the summer. These were a direct result of the
data that came back from our advanced cancer study. One of those
patents is for Car-T Cell
sickness or Cytokine Release
Syndrome. Car-T is one
of the
most advanced FDA approved immunotherapies on the
market. Our data from the
cancer study supports the use of NanoStilbene to suppress the
cytokine storm of Car-T sickness.
We were also greatly
honored when Wes Chandler of NFL fame brought to our
attention Chronic Traumatic
Encephalopathy or
CTE,
a condition that affects sports players and others who receive
repetitive concussions and head injuries. We quickly formed a CTE
advisory board with Wes as Chairman to explore CTE and have since
filed two CTE related patents. One for prevention of
CTE
we call
NeuroStilbene and one for
therapeutic treatment of
CTE with enhanced
stem
cells.
Next on the CTE
project was to find a cellular product that would qualify under
"Right To
Try" and
we found that product in the form of mesenchymal stem cells. On Dec
10 we announced licensing of the Jadi Cell universal donor
adult stem cell for use in Chronic Traumatic Encephalopathy (CTE),
and Traumatic Brain Injury (TBI). Our intent is to have these cells
available in early
2019
under RTT.
I know there are many
moving parts at TSOI and some of it is years away like the
9,682,047
patent
was in July 2015 when we filed, but here we are wrapping up 2018
with a human validated and a patent granted
product, NanoStilbene. Looking
to 2019 the key things you will see from us will be the promotion
of NanoStilbene and
NeuroStilbene and
the
"Right
To
Try" use
of stem cells and eventually our dendritic cell vaccine for
cancer,
StemVacs.
A Special Thank You
to my science and medical team for all of their hard work this past
year and for the hard work left ahead of us that they are committed
to. We are looking forward to 2019 as an important year for TSOI
and we thank all of you for your patience and wish you a Happy New
Year from everyone at TSOI. For a more detailed
release visit us on https://www.facebook.com/tsoihome/
Sincerely
yours,
Tim G Dixon,
President & CEO
About
Therapeutic Solutions International, Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com.
These statements have
not been evaluated by the Food and Drug Administration. These
products are not intended to diagnose, treat, cure, or prevent any
disease.
Safe Harbor
Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
Contact
Information:
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Apr 2024 to May 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From May 2023 to May 2024